Tohru Morisada

Tohru Morisada

Auto-generated profile, based on publicly available information

Tohru Morisada

Department of Obstetrics and Gynecology, Kyorin University Faculty of Medicine, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2018 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
HNHiroshi Nishio
Hiroshi Nishio
TITakashi Iwata
Takashi Iwata
HNHidetaka Nomura
Hidetaka Nomura
TMTohru Morisada
Tohru Morisada
NTNobuhiro Takeshima
Nobuhiro Takeshima
DADaisuke Aoki
Daisuke Aoki
Liquid-based cytology (LBC) and conventional cytology (CS) are routine diagnostic techniques in cervical cytology, but few studies have compared their diagnostic performances with each other and with histologic diagnosis. This study aimed to compare the diagnostic performances of these techniques in subjects with abnormal cervical cytology of atypical cells of undetermined significance (ASC-US) or worse. A total of 312 patients diagnosed with ASC-US or worse were enrolled in this prospective study in Japan from 2013 to 2014. LBC and CS samples were prepared by a split-sampling technique and evaluated blindly. The results were classified using the Bethesda System 2001. Colposcopy and biopsy were conducted simultaneously or within 4 weeks of cytology-specimen collection in all cases. Diagnostic performance was calculated in terms of sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for detection of CIN2 or worse, with a cut-off ASC-US or worse. There was one unsatisfactory CS sample and the remaining 311 cases were evaluated. The sensitivities of LBC and CS were 100.0% and 98.8%, specificities were 17.2% and 23.8%, PPVs were 56.1% and 57.9% and NPVs were 100.0% and 94.7%, respectively. LBC had slightly higher sensitivity and NPV for detection of CIN2, but there was no significant difference between the two methods. There was no significant difference in the diagnostic performances of LBC and CS in patients with ASC-US or worse. LBC may therefore be an alternative approach to CS for cervical cancer screening.

16 April 2024 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Open access
PDF file
ENEiji Nishio
Eiji Nishio
KIKen Ishitani
Ken Ishitani
TATakahide Arimoto
Takahide Arimoto
TIToshio Igarashi
Toshio Igarashi
TITetsuya Ishikawa
Tetsuya Ishikawa
TFTakuma Fujii
Takuma Fujii
Twelve years after the first edition of The Guideline for Gynecological Practice, which was jointly edited by The Japan Society of Obstetrics and Gynecology and The Japan Association of Obstetricians and Gynecologists, the 5th Revised Edition was published in 2023. The 2023 Guidelines includes 5 additional clinical questions (CQs), which brings the total to 103 CQ (12 on infectious disease, 30 on oncology and benign tumors, 29 on endocrinology and infertility and 32 on healthcare for women). Currently, a consensus has been reached on the Guidelines, and therefore, the objective of this report is to present the general policies regarding diagnostic and treatment methods used in standard gynecological outpatient care that are considered appropriate. At the end of each answer, the corresponding Recommendation Level (A, B, C) is indicated.

1 January 2025 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
TMTohru Morisada
Tohru Morisada
YKYoichi Kobayashi
Yoichi Kobayashi
SNSatoru Nagase
Satoru Nagase
TBTsukasa Baba
Tsukasa Baba
HTHideki Tokunaga
Hideki Tokunaga
MMMikio Mikami
Mikio Mikami
Morisada T, et al. J Gynecol Oncol. 2025 Apr;36(3):e119. https://doi.org/10.3802/jgo.2025.36.e119

6 March 2023 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
IMIsao Murakami
Isao Murakami
HMHiroko Machida
Hiroko Machida
TMTohru Morisada
Tohru Morisada
YTYasuhisa Terao
Yasuhisa Terao
TTTsutomu Tabata
Tsutomu Tabata
SNSatoru Nagase
Satoru Nagase
Murakami I, et al. J Gynecol Oncol. 2023 Mar;34:e49. https://doi.org/10.3802/jgo.2023.34.e49

1 January 2021 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
KKKanako Kono
Kanako Kono
TMTohru Morisada
Tohru Morisada
KSKumiko Saika
Kumiko Saika
EAEiko Saitoh Aoki
Eiko Saitoh Aoki
Etsuko MiyagiEtsuko Miyagi
Etsuko Miyagi
DADaisuke Aoki
Daisuke Aoki
Kono K, et al. J Gynecol Oncol. 2021 Jan;32(3):e29. https://doi.org/10.3802/jgo.2021.32.e29

1 January 2023 in JCO Global Oncology
Verified
Journal Article
Open access
TOToshio Ogawa
Toshio Ogawa
HTHirokazu Takahashi
Hirokazu Takahashi
HSHiroshi Saito
Hiroshi Saito
MSMotoyasu Sagawa
Motoyasu Sagawa
DADaisuke Aoki
Daisuke Aoki
TSTomotaka Sobue
Tomotaka Sobue
PURPOSE: We developed algorithms to identify patients with newly diagnosed cancer from a Japanese claims database to identify the patients with newly diagnosed cancer of the sample population, which were compared with the nationwide cancer incidence in Japan to assess the validity of the novel algorithms. METHODS: We developed two algorithms to identify patients with stomach, lung, colorectal, breast, and cervical cancers: diagnosis only (algorithm 1), and combining diagnosis, treatments, and medicines (algorithm 2). Patients with newly diagnosed cancer were identified from an anonymized commercial claims database (JMDC Claims Database) in 2017 with two inclusions/exclusion criteria: selecting all patients with cancer (extract 1) and excluding patients who had received cancer treatments in 2015 or 2016 (extract 2). We estimated the cancer incidence of the five cancer sites and compared it with the Japan National Cancer Registry incidence (calculated standardized incidence ratio with 95% CIs). RESULTS: The number of patients with newly diagnosed cancer ranged from 219 to 17,840 by the sites, algorithms, and exclusion criteria. Standardized incidence ratios were significantly higher in the JMDC Claims Database than in the national registry data for extract 1 and algorithm 1, extract 1 and algorithm 2, and extract 2 and algorithm 1. In extract 2 and algorithm 2, colorectal cancer in male and stomach, lung, and cervical cancers in females showed similar cancer incidence in the JMDC and national registry data. CONCLUSION: The novel algorithms are effective for extracting information about patients with cancer from claims data by using the combined information on diagnosis, procedures, and medicines (algorithm 2), with 2-year cancer-treatment history as an exclusion criterion (extract 2).